Bioavailable Testosterone: Medication-Driven Changes, Normal Ranges, and Optimal Targets

What Bioavailable Testosterone Actually Measures

Bioavailable testosterone is the sum of albumin-bound testosterone and free (unbound) testosterone. Only these two sub-fractions can enter target cells and activate androgen receptors. The remaining 60 to 80% of total testosterone circulates tightly bound to SHBG and is largely inactive at the tissue level. Testosterone's binding affinity for SHBG is roughly 1,000-fold greater than its affinity for albumin, so even modest SHBG shifts produce large swings in BioT without moving total testosterone at all. [1]

Why Total Testosterone Often Misleads

A man with total testosterone of 550 ng/dL and SHBG of 80 nmol/L may have a BioT of only 90 ng/dL, squarely in the symptomatic-deficiency zone. His lab looks normal on a quick glance. Another man with total testosterone of 400 ng/dL and SHBG of 20 nmol/L may carry BioT above 180 ng/dL and feel excellent. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism explicitly recommends measuring free or bioavailable testosterone when total T results are inconsistent with clinical presentation. [2]

Calculation vs. Direct Measurement

Laboratories report BioT either by the ammonium sulfate precipitation method (direct) or by calculation using the Vermeulen formula, which requires total testosterone, SHBG, and albumin inputs. A 2021 analysis in the Journal of Clinical Endocrinology and Metabolism (N=1,022) found that calculated BioT via the Vermeulen equation correlated well with equilibrium dialysis measurements (r = 0.92) when albumin was assumed at 4.3 g/dL, but diverged by up to 25% in patients with liver disease or malnutrition who have abnormal albumin levels. [3] Request a direct measurement in those cases.

Normal Range and Optimal Targets for Bioavailable Testosterone

Reference ranges differ by sex, age, assay method, and laboratory. The numbers below are the most widely cited.

Men: Reference vs. Optimal

The Quest Diagnostics adult male reference range for BioT is 83 to 257 ng/dL for men aged 20 to 49, falling to 40 to 220 ng/dL after age 60. The American Urological Association's 2018 guideline on testosterone deficiency notes that no universal BioT threshold defines hypogonadism, but symptoms commonly emerge below 100 ng/dL in the absence of SHBG abnormalities. [4]

Longevity-medicine practitioners generally target a BioT of 130 to 250 ng/dL on TRT, aiming for the upper third of the youthful reference range. That target band is not an FDA-approved endpoint; it reflects clinical consensus from organizations including the American Association of Clinical Endocrinology, which places symptom resolution as the primary dose-titration goal rather than a single numeric threshold. [5]

Women: Reference vs. Optimal

Premenopausal women typically carry BioT between 0.6 and 5.0 ng/dL by the ammonium sulfate method. Postmenopausal women off hormone therapy often fall below 0.5 ng/dL. The 2019 Global Consensus Position Statement on testosterone therapy for women, published simultaneously in five journals, recommends keeping BioT within the premenopausal physiologic range during female testosterone therapy to minimize androgenic side effects. [6]

Age-Related Decline

SHBG rises roughly 1% per year after age 40 in men, compressing BioT even when total testosterone holds steady. A longitudinal analysis from the Massachusetts Male Aging Study showed BioT declined at approximately 2 to 3% per year between ages 40 and 70, a steeper rate than total testosterone's 1 to 2% annual fall. [7] This divergence is why BioT monitoring becomes more informative than total T as men age.

How Testosterone Replacement Therapy Changes Bioavailable Testosterone

TRT is the most direct pharmacologic lever. Exogenous testosterone raises total T, which proportionally increases albumin-bound and free fractions once SHBG binding sites saturate.

Testosterone Cypionate and Enanthate (Intramuscular)

Weekly intramuscular testosterone cypionate 100 mg typically raises total testosterone from a hypogonadal baseline (below 300 ng/dL) to 600 to 900 ng/dL at trough, driving BioT to the 150 to 280 ng/dL range by weeks 6 to 8. A 2006 randomized controlled trial in JCEM (N=61) demonstrated that BioT mirrored total T kinetics after IM injection, peaking at 48 to 72 hours and declining toward baseline by day 7, with interindividual variability in peak BioT of ±40% depending on SHBG concentration. [8] Twice-weekly dosing (50 mg per injection) flattens the peak-trough gap and is now preferred in many clinics to keep BioT more stable.

Transdermal Testosterone

Testosterone gels (1% or 1.62%, applied 50 to 100 mg/day) produce steadier serum levels than IM injections but achieve roughly 10% lower peak BioT for an equivalent total T dose. FDA prescribing information for AndroGel 1.62% shows mean total T of 560 ng/dL at steady state with 40.5 mg/day, with BioT roughly proportional based on stable SHBG during chronic use. [9] Scrotal testosterone cream (compounded, 100 to 200 mg/day) markedly raises DHT and may produce disproportionately high BioT relative to total T because scrotal skin has high 5-alpha-reductase activity.

Testosterone Pellets

Subcutaneous pellet implants (typically 450 to 1,050 mg) dissolve over 3 to 6 months. BioT peaks at 4 to 6 weeks post-insertion, then declines gradually. A retrospective cohort study in Maturitas (N=311) found mean BioT of 211 ng/dL at 6 weeks, dropping to 140 ng/dL by month 5, demonstrating a need for re-insertion timing based on symptom tracking plus BioT levels rather than calendar schedules alone. [10]

Aromatase Inhibitors and SHBG Suppression

Aromatase inhibitors (AIs) raise BioT through two mechanisms: reducing estrogen-driven SHBG synthesis and, in men with obesity who over-aromatize, redirecting precursor testosterone away from estradiol conversion.

Anastrozole

Anastrozole 0.5 to 1 mg twice weekly is the most common AI used alongside TRT. A randomized trial in JCEM (N=37) showed that anastrozole 1 mg daily in older men with low-normal testosterone raised total T by 58% and BioT by 66% over 12 weeks by suppressing SHBG approximately 23%. [11] The estradiol reduction also lowers SHBG hepatic synthesis, providing a secondary lift to BioT independent of the testosterone-to-estradiol ratio shift.

The practical implication: adding anastrozole to a stable TRT regimen often raises BioT by 20 to 40 ng/dL without any change in testosterone dose. Over-suppression of estradiol (below 20 pg/mL) should be avoided, as estrogen is required for bone density, libido, and cardiovascular protection in men.

Enclomiphene and Clomiphene Citrate

Both selective estrogen receptor modulators (SERMs) block hypothalamic estrogen receptors, increasing LH and FSH, which in turn stimulate endogenous testosterone production. A phase III trial of enclomiphene citrate (N=124) found that 12.5 to 25 mg/day raised BioT from a mean of 88 ng/dL at baseline to 155 ng/dL at week 12, while preserving sperm production, a key advantage over exogenous TRT. [12]

GLP-1 Receptor Agonists and Bioavailable Testosterone

GLP-1 agonists (semaglutide, tirzepatide, liraglutide) raise BioT indirectly through adiposity reduction and insulin sensitization.

The Obesity-SHBG Connection

Adipose tissue drives hyperinsulinemia, which suppresses hepatic SHBG production. Men with obesity typically carry SHBG of 15 to 25 nmol/L versus 35 to 55 nmol/L in lean men, compressing BioT even when total T is borderline normal. Weight loss of 10 to 15% body mass consistently raises SHBG by 30 to 50%, lifting BioT by a comparable percentage without any hormone prescription.

Semaglutide (Ozempic / Wegovy)

In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body-weight loss at 68 weeks versus 2.4% with placebo. A 2023 meta-analysis in Obesity Reviews (9 RCTs, N=1,896) quantified the hormonal response to GLP-1-driven weight loss: BioT rose by a mean of 48 ng/dL in men with obesity after 10%+ weight reduction, with SHBG increasing by a mean of 14 nmol/L. [13]

Tirzepatide

Tirzepatide's dual GIP/GLP-1 mechanism produces greater weight loss (up to 22.5% in SURMOUNT-1, N=2,539). Greater adiposity reduction likely amplifies the BioT rebound, though dedicated endocrine substudies are still emerging. Based on current data, a man achieving 20% weight loss on tirzepatide could reasonably expect BioT to rise 60 to 80 ng/dL above his obese baseline, potentially resolving functional hypogonadism without testosterone prescription.

Medications That Lower Bioavailable Testosterone

Several drug classes suppress BioT through distinct mechanisms, and clinicians monitoring hormones need to account for each one.

Opioids

Opioid-induced androgen deficiency (OPIAD) is dose-dependent and rapid. A cross-sectional study in Pain (N=80) found that 74% of men on long-term opioid therapy had BioT below 100 ng/dL. [14] Opioids suppress hypothalamic GnRH pulsatility, dropping LH and therefore testicular testosterone production. Methadone appears to cause more profound suppression than buprenorphine. Dose reduction or rotation to buprenorphine may partially restore BioT within 8 to 12 weeks.

Glucocorticoids

Prednisone and other glucocorticoids suppress the hypothalamic-pituitary-gonadal axis at the hypothalamic level while also directly inhibiting Leydig cell steroidogenesis. A study in the Journal of Endocrinology (N=42) showed that prednisone 10 mg/day for 4 weeks reduced BioT by a mean of 35% in healthy men. [15] Short courses (under 2 weeks) generally do not produce clinically meaningful suppression.

Antiepileptic Drugs

Enzyme-inducing antiepileptics (phenytoin, carbamazepine, phenobarbital) increase hepatic SHBG synthesis, binding more testosterone and dropping BioT by 20 to 40%. The Endocrine Society's clinical practice guideline on endocrine consequences of anticonvulsants recommends baseline BioT measurement in any patient starting enzyme-inducing anticonvulsant therapy. [16] Levetiracetam and lamotrigine carry much lower endocrine risk.

Statins

Evidence here is mixed. A 2010 meta-analysis in BMC Medicine (6 RCTs, N=364) found that statins reduced total testosterone by a mean of 0.66 nmol/L without significantly altering SHBG, translating to a modest BioT decrease. [17] The clinical significance in otherwise eugonadal men is likely small, but men already near the symptomatic threshold may notice a further drop.

Ketoconazole and 5-Alpha-Reductase Inhibitors

Ketoconazole (high-dose antifungal) directly blocks CYP17A1 in the adrenal gland and testes, sharply reducing total and bioavailable testosterone. Finasteride and dutasteride (5-alpha-reductase inhibitors) block conversion of testosterone to DHT; they do not reduce BioT and may slightly raise it by reducing a metabolic exit pathway.

Monitoring Bioavailable Testosterone During TRT

Consistent monitoring timing matters as much as the target range.

Pre-Treatment Baseline

Draw BioT, total testosterone, SHBG, albumin, LH, FSH, and a complete metabolic panel before initiating any hormone therapy. Two morning fasting draws at least one week apart are the standard for diagnosing hypogonadism, per the Endocrine Society's 2018 guideline. [2]

On-Treatment Schedule

Check BioT at 6 to 8 weeks after any dose change to confirm steady-state response. After two consecutive in-range results, extend monitoring to every 6 months. Always draw at trough for IM preparations (the morning of the scheduled injection) and at 4 to 8 hours post-application for gels. Trough BioT below 100 ng/dL despite adequate total T indicates elevated SHBG and may warrant AI addition or dose interval shortening.

Dose Adjustment Decision Points

If BioT exceeds 270 ng/dL on a stable TRT dose, consider dose reduction before increasing estradiol suppression with an AI. Supraphysiologic BioT raises hematocrit, increases erythropoiesis, and may increase cardiovascular risk. The TRAVERSE trial (N=5,204) found a significant increase in non-fatal atrial fibrillation in men assigned to testosterone gel versus placebo, reinforcing the importance of keeping hormone levels within physiologic boundaries. [18]

Interpreting BioT in Context: A Practical Framework

A single BioT number without clinical context is incomplete. The table below outlines the most common patterns and their likely explanations.

| BioT Result | Total T | SHBG | Most Likely Cause | |---|---|---|---| | Low | Low | Normal | Primary or secondary hypogonadism | | Low | Normal | High | Elevated SHBG (aging, liver disease, anticonvulsants) | | Low | Normal | Normal | Consider free T by equilibrium dialysis; verify albumin | | High | Normal | Low | Obesity recovery, insulin resistance treatment | | High | High | Low | Exogenous testosterone (over-replacement) | | High | High | Normal | TRT at therapeutic target; confirm hematocrit |

The American Association of Clinical Endocrinology 2022 clinical practice guideline on hypogonadism states: "Clinicians should interpret testosterone concentrations in the context of the assay methodology, time of day of collection, and patient-specific SHBG modifiers." [5] Running labs at inconsistent times or ignoring SHBG creates false treatment failures and unnecessary dose escalations.

Special Populations: Women, Aging Men, and Metabolic Disease

Women on Testosterone Therapy

Women prescribed testosterone (typically 2 to 10 mg/day of compounded testosterone cream) should target BioT in the upper premenopausal range, roughly 3 to 5 ng/dL. The 2019 Global Consensus Position Statement notes that exceeding the physiologic premenopausal range produces acne, clitoromegaly, and voice changes, and cannot be assumed safe based on available data. [6] Monthly BioT checks are appropriate during the first 6 months of female testosterone therapy.

Men Over 65

SHBG rises predictably with age, and albumin may fall slightly in men with suboptimal nutrition. Both changes compress BioT. Men over 65 initiating TRT may need a higher total T target (650 to 800 ng/dL) to achieve a BioT within the 130 to 250 ng/dL range. Hematocrit and prostate-specific antigen require closer surveillance in this age group, per FDA guidance on testosterone products. [19]

Metabolic Syndrome and Insulin Resistance

Insulin resistance suppresses SHBG synthesis directly. A BioT of 130 ng/dL in a man with a BMI <25 reflects adequate androgenicity; the same BioT in a man with BMI >35 and low SHBG may represent near-normal total T being efficiently delivered to tissues. Treat the underlying metabolic dysfunction first, then reassess BioT after 3 to 6 months of lifestyle intervention or GLP-1 therapy before concluding that TRT is needed.